Sunovion Discontinues Dasotraline Program

May 13, 2020 -- MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has withdrawn the New Drug Applications (NDAs) for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials